🇺🇸 Oxybutynin Cl in United States

54 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 8 reports (14.81%)
  2. Drug Ineffective — 7 reports (12.96%)
  3. Fall — 5 reports (9.26%)
  4. Fatigue — 5 reports (9.26%)
  5. Headache — 5 reports (9.26%)
  6. Product Substitution Issue — 5 reports (9.26%)
  7. Urinary Tract Infection — 5 reports (9.26%)
  8. Vomiting — 5 reports (9.26%)
  9. Weight Decreased — 5 reports (9.26%)
  10. Chronic Kidney Disease — 4 reports (7.41%)

Source database →

Oxybutynin Cl in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Oxybutynin Cl approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Oxybutynin Cl in United States?

Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.